carboplatin + cisplatin + docetaxel + gemcitabine + paclitaxel + pemetrexed + vinorelbine

This is a combination of seven chemotherapeutic agents, each with distinct mechanisms of action and clinical uses. The combination is not a standard or widely recognized regimen in oncology practice, but each drug individually or in smaller combinations (such as carboplatin/docetaxel, cisplatin/docetaxel, etc.) has been studied for various cancers including ovarian cancer, non-small cell lung cancer (NSCLC), and carcinoma of unknown primary site[1][2][4]. The rationale for combining these agents would be to target multiple pathways involved in tumor growth and resistance; however, such a large combination is rarely used due to overlapping toxicities and lack of evidence for improved efficacy over established doublet or triplet regimens.